HSR21-051: Treatment Outcomes Among HR+/HER2- Advanced/Metastatic Breast Cancer Patients Receiving CDK 4 & 6 Inhibitors in a United States Clinical Practice Setting

View More View Less
  • 1 Eli Lilly and Company, Indianapolis, IN
  • | 2 Texas Oncology - The Woodlands, The Woodlands, TX
  • | 3 McKesson Life Sciences, The Woodlands, TX
Restricted access

Corresponding Author: Yu-Jing Huang, PhD